Wisnu W, Alwi I, Nafrialdi N, Pemayun T, Pantoro N, Wijaya C
J Lipid Atheroscler. 2024; 13(3):358-370.
PMID: 39355401
PMC: 11439756.
DOI: 10.12997/jla.2024.13.3.358.
Khan A, Ata F, Aziz A, Elamin H, Shahzad A, Yousaf Z
J Endocr Soc. 2024; 8(1):bvad133.
PMID: 38178906
PMC: 10765380.
DOI: 10.1210/jendso/bvad133.
Wu Y, Chang Y, Tsai C, Chan Y, Chi S, Chou F
Sci Rep. 2023; 13(1):2764.
PMID: 36797361
PMC: 9935526.
DOI: 10.1038/s41598-023-29885-2.
Kanokwongnuwat W, Penpong N, Sangsri C
Thyroid Res. 2022; 15(1):24.
PMID: 36529758
PMC: 9761999.
DOI: 10.1186/s13044-022-00142-4.
Lertwattanarak R, Kunavisarut T, Sriussadaporn S
Int J Endocrinol. 2022; 2022:1705740.
PMID: 36267362
PMC: 9578883.
DOI: 10.1155/2022/1705740.
Audit of long-term treatment outcomes of thyrotoxicosis in a single-centre virtual clinic: The utility of long-term antithyroid drugs.
Levy M, Reddy N, Price D, Bhake R, Bremner E, Barrowcliffe M
Clin Endocrinol (Oxf). 2022; 97(5):643-653.
PMID: 35274339
PMC: 9790704.
DOI: 10.1111/cen.14721.
Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis.
Lin S, Wei Y, Yao H
Int J Gen Med. 2021; 14:9707-9718.
PMID: 34934347
PMC: 8684403.
DOI: 10.2147/IJGM.S339946.
Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'.
Sjolin G, Bystrom K, Holmberg M, Torring O, Khamisi S, Calissendorff J
Endocrinol Diabetes Metab. 2021; 4(3):e00244.
PMID: 34277969
PMC: 8279596.
DOI: 10.1002/edm2.244.
Antithyroid Drug Treatment in Graves' Disease.
Chung J
Endocrinol Metab (Seoul). 2021; 36(3):491-499.
PMID: 34130446
PMC: 8258321.
DOI: 10.3803/EnM.2021.1070.
Transient Leukopenia After Radioactive Iodine Treatment in Patients With Graves' Disease: A Retrospective Cohort Study.
Yamashita K, Morimoto S, Kimura S, Seki Y, Bokuda K, Watanabe D
J Endocr Soc. 2021; 5(5):bvab039.
PMID: 33928204
PMC: 8064043.
DOI: 10.1210/jendso/bvab039.
Efficacy of low-dose methimazole in control of multiple relapses of Graves' hyperthyroidism: a case report.
Azizi F, Amouzegar A, Abdi H
J Med Case Rep. 2021; 15(1):189.
PMID: 33888159
PMC: 8063397.
DOI: 10.1186/s13256-021-02788-4.
Is There Any Need for Adjusting I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis.
Arora S, Bal C
Nucl Med Mol Imaging. 2021; 55(1):15-26.
PMID: 33643485
PMC: 7881070.
DOI: 10.1007/s13139-020-00674-3.
A Clinical Debate: What Is the Therapeutic Choice for Recurrent Graves' Hyperthyroidism?.
Abdi H, Zakavi S, Azizi F
Int J Endocrinol Metab. 2021; 18(4):e108876.
PMID: 33613682
PMC: 7887460.
DOI: 10.5812/ijem.108876.
Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse n Methimazole-Treated Graves Disease.
Thewjitcharoen Y, Karndumri K, Chatchomchuan W, Porramatikul S, Krittiyawong S, Wanothayaroj E
J Endocr Soc. 2020; 5(1):bvaa170.
PMID: 33305160
PMC: 7716657.
DOI: 10.1210/jendso/bvaa170.
Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism.
Namwongprom S, Dejkhamron P, Unachak K
J Endocrinol Invest. 2020; 44(3):541-545.
PMID: 32583373
DOI: 10.1007/s40618-020-01339-w.
Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.
Zarkovic M, Wiersinga W, Perros P, Bartalena L, Donati S, Okosieme O
J Endocrinol Invest. 2020; 44(2):371-378.
PMID: 32524368
DOI: 10.1007/s40618-020-01320-7.
Predictors of euthyreosis in hyperthyroid patients treated with radioiodine I: a retrospective study.
Stachura A, Gryn T, Kaluza B, Budlewski T, Franek E
BMC Endocr Disord. 2020; 20(1):77.
PMID: 32487052
PMC: 7268615.
DOI: 10.1186/s12902-020-00551-2.
Diagnosis and Management of Graves' Disease in Thailand: A Survey of Current Practice.
Sriphrapradang C
J Thyroid Res. 2020; 2020:8175712.
PMID: 32454522
PMC: 7238361.
DOI: 10.1155/2020/8175712.
Shifting Trends and Informed Decision-Making in the Management of Graves' Disease.
Seib C, Chen J, Iagaru A
Thyroid. 2020; 30(3):351-354.
PMID: 32046610
PMC: 7074894.
DOI: 10.1089/thy.2020.0114.
Comparison Between the Treatment Modalities for Graves' Disease at King Abdulaziz Medical City, Jeddah.
Zarif H, Alam S, Baashar A, Alsharif A, Alhilabi M
Cureus. 2020; 12(1):e6730.
PMID: 32015936
PMC: 6977577.
DOI: 10.7759/cureus.6730.